MDX-010

DRUG5 trials

Sponsors

Bristol-Myers Squibb, National Cancer Institute (NCI)

Conditions

AdenocarcinomaBreast CancerHuman Immunodeficiency Virus (HIV)Malignant MelanomaNeoplasm MetastasisProstate CancerProstatic Neoplasms

Phase 1

Vaccine and Antibody Treatment of Prostate Cancer

CompletedNCT00113984

National Cancer Institute (NCI)Prostatic Neoplasms

Start: 2005-06-08End: 2011-12-01Updated: 2019-12-16

Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer

CompletedNCT00323882

Bristol-Myers SquibbNeoplasm Metastasis, Prostate Cancer

Start: 2006-01-31End: 2013-07-31Updated: 2014-08-28

Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

CompletedNCT00729950

Bristol-Myers SquibbMalignant Melanoma

Start: 2003-07-31End: 2007-06-30Updated: 2010-04-26

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

CompletedNCT03407105

Bristol-Myers SquibbHuman Immunodeficiency Virus (HIV)

Start: 2003-04-21End: 2006-02-21Updated: 2018-01-23

Phase 2

Study of MDX-010 in Stage IV Breast Cancer

CompletedNCT00083278

Bristol-Myers SquibbAdenocarcinoma, Breast Cancer

Start: 2003-05-31End: 2006-02-28Updated: 2012-04-27

Related Papers

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

PLoS ONE2018-06-0725 citations

Abstract 1694: Systemic granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment increases T cell receptor diversity in localized and metastatic prostate cancer patients

Cancer Research2017-07-01

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.

Journal of Clinical Oncology2015-05-204 citations

Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.

Journal of Clinical Oncology2015-03-0112 citations

Abstract 5012: A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates

Cancer Research2014-10-011 citations

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

2013-03-27412 citations

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

2012-02-10253 citations